Someone on the Board of directors with some serious voting power slammed the meeting down. I think this is great. HEPA is holding back on a wide array of updates on multiple indications. If you think about this it's the best thing that could of happened.
Again Those who don't know the most basic stuff, like the difference between authorized shares and issued shares, really shouldn't be trading stocks at all, but then they won't be around for very long, so!
I will buy one more large chunk under 2.30 Monday if the opportunity presents itself. Look at the 3 month chart on ATOS and HEPA is looking like the ATOS chart three months ago. Hovering mid 1.40's range and boom had a market cap of under 200 million and hit a billion before the a pullback Friday at the close.
Also this is key! Most importantly there are 76 million HEPA shares outstanding. >95% institutional ownership.
No filings were submitted for ~70% of the 64 million shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64 million shares at those offerings, there were 12 million shares out, with 3 million in the public float. So, direct holders had ~9 million shares of that, and tutes got 64 million shares at the offerings, which possibly left ~3 million shares for retail then. Also the chart is golden for upward continuation for the foreseeable future IMO going int0 2022 & beyond.
"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous." -NIH
NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
HEPA With a NASH & the dozen other possible applications HEPA is looking at this can be trading 100x from currents levels.
Nash Companies in Phase 2 & 3 Trials by companies in the NASH space: AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash. MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash. HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash.
Russell 2000 buying starts next week as well for HEPA lots of catalysts on top! be patient & lock up your shares! & accumulate at these levels IMO
News 
Market Data 
Discover 
